INTRODUCTION
ethanol (Et-OH).
2) Assessment of inflammation and histology
Mice were weighed daily. Body weight loss was determined by percentage of weight loss from baseline body weight. Mice were sacrificed on each 3 (n=10) and 10 days (n=10) after the TNBS administration. The longitudinally 
4) Statistical analysis
Statistical analysis was done using Graphpad Prism (ver.
4). Results were expressed as the mean±standard deviation (SD). Groups of data were compared using Student's t-test.
Statistical significance was established at P＜0.05.
RESULTS

1) Measurement of survival rate and weight loss
To investigate the role of MSC in experimental colitis rate of approximately 60% after 10 days (Fig. 1) . TNBS colitic mice treated with MSCs showed a markedly increased survival rate of 90% compared to TNBS colitic mice of 40% (Fig. 1 ).
Similar decrease in body weight was observed in both TNBS colitic mice and MSC treated colitic mice at day 1 (Fig. 2) . Decrease in body weight (maximum of more than 10%) was observed until day 3 followed by gradual recovery in TNBS colitic mice (Fig. 2) . However, MSC treated colitic mice showed no further weight loss after day 1 and showed rapid weight recovery (Fig. 2) .
Thus, MSC treatment in colitis-induced mice resulted in increased survival rate and decreased weight loss.
2) Assessment of H&E staining
After H&E staining and scores were compiled for each mouse, statistically significant differences were observed in the subject in the involved region and alteration & erosion on day 10 in MSC treated mice (Table 1, Fig. 3 ).
3) Flow cytometric analysis
Induction of TNBS colitis resulted in a slight decrease in CD4
＋ T cells in the blood and spleen (except day 10 in spleen), whereas MSC treatment showed increase in it.
CD8a
＋ T cells showed a slight decrease after TNBS treatment in both blood and spleen samples, but increased after MSC treatment. CD19 ＋ T cells in the spleen showed a 30∼40% decrease in the TNBS group compared to control/Et-OH group, but showed a dramatic decrease after MSC treatment, and CD4 ＋ CD25 ＋ T cells showed a marked increase in TNBS/MSC group compared to TNBS group in the blood on day 3 ( Table 2 ).
4) Measurement of cytokine production in culture medium
In order to determine the treatment effect of MSC in TNBS colitis, splenocytes producing various cytokines were cultured and ELISA was performed.
Concentrations of IFN-γ and IL-12 from the Th1 group (IFN-γ, TNF-α, IL-12) were significantly lower in the MSC treated group compared to the control (Et-OH) and TNBS groups, and concentrations of TNF-α were significantly higher in the MSC treated group compared to the TNBS group on day 3 but markedly decreased by day 10 which showed that there is a decreasing effect on pro-inflammatory markers (Fig. 4) . IL-10) was significantly lower in the MSC treated group compared to the TNBS group on day 10. In contrast, the concentration of IL-6 was significantly higher in the MSC treated group on day 3. The concentration of IL-10 on day 3 showed no noticeable differences in all 3 groups, but the MSC treated group showed a significant increase on day 10 compared to the TNBS group (Fig. 4) .
Concentration of IL-4 in the Th2 group (IL-4, IL-6,
DISCUSSION
In this study, we examined the effects of MSC on TNBS-induced colitis, which is a CD4 ＋ T-cell mediated autoimmune disease.
Clinical results from H&E staining showed a significant decrease in both the microscopic inflammatory process and in damage in the TNBS/MSC group compared to the TNBS group. On day 10, all of the involved regions showed a significant decrease in alteration and erosion.
Mononuclear cell infiltration was also decreased, but was not statistically significant. These are all signs of a decrease in the inflammatory process, which proves that MSC has an anti-inflammatory effect on microscopic inflammation. However, cell surface markers from the TNBS group yielded different results. CD8a (blood, day 4) and CD4
(blood and spleen, day 10) in the TNBS/MSC group all showed a significant increase compared to the TNBS group, which shows that there is still inflammation and a Th1
response. This could have been due to a remaining inflammatory process that was not attenuated by MSCs.
Also, TNF-α levels did not correlate with other cytokine levels. TNF-α levels significantly increased on day 3 in the TNBS/MSC group compared to the TNBS group, which
shows that there is a significant inflammatory process present. This result did not correlate with other cytokine levels which all showed a decrease, signifying a decreased inflammatory process. Whereas this study showed no significant decrease in the TNF-α levels by MSCs, Lee et al. (29, 30) showed that DSG and anti-4-1 BB mAb leads to a decrease in TNF-α levels. However, TNF-α significantly increased only on day 3 but not on day 10 in this study, which can be interpreted as MSCs working more effectively in the later part of the inflammation process and not in the earlier part. Also, results from H&E staining showed a significant decrease in the microscopic inflammatory process on day 10 which correlates to the lack of a significant rise in these cytokine levels by then.
There is much research being done on the use of MSCs in treating intestinal diseases. It has been shown that adipose-derived MSCs can be used to treat rectovaginal fistulas in perianal CD without any adverse effects. (31) Research has suggested a great potential for the application of MSC. However, the mechanism of action still requires more in depth clarification, which will provide the direction and focus for future study. The current study would have been able to yield more reliable results if the sample sizes were larger. The addition of an apoptosis detection assay to monitor the decrease in specific cell populations would also have given more accurate findings.
In addition, monitoring other cytokines such as CD11 
